|
1
|
The endothelin axis: emerging role in cancer.
|
Nat Rev Cancer
|
2003
|
2.81
|
|
2
|
Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells.
|
Cancer Res
|
2005
|
1.69
|
|
3
|
Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis.
|
Proc Natl Acad Sci U S A
|
2009
|
1.59
|
|
4
|
Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells.
|
J Biol Chem
|
2002
|
1.56
|
|
5
|
Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
|
Clin Cancer Res
|
2011
|
1.53
|
|
6
|
Endothelin 1 in cancer: biological implications and therapeutic opportunities.
|
Nat Rev Cancer
|
2013
|
1.40
|
|
7
|
Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation.
|
Mol Pharmacol
|
2002
|
1.34
|
|
8
|
Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade.
|
Cancer Res
|
2009
|
1.19
|
|
9
|
Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma.
|
Mol Cancer Ther
|
2006
|
1.08
|
|
10
|
Endothelin-1 decreases gap junctional intercellular communication by inducing phosphorylation of connexin 43 in human ovarian carcinoma cells.
|
J Biol Chem
|
2003
|
1.05
|
|
11
|
Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
|
Cancer Res
|
2003
|
1.03
|
|
12
|
Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1alpha in human melanoma cells.
|
Cancer Res
|
2007
|
1.03
|
|
13
|
Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion.
|
J Biol Chem
|
2004
|
1.00
|
|
14
|
Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
|
Clin Cancer Res
|
2004
|
0.99
|
|
15
|
Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells.
|
PLoS One
|
2010
|
0.98
|
|
16
|
Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity.
|
Cancer Res
|
2007
|
0.98
|
|
17
|
ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
|
Mol Cancer Ther
|
2007
|
0.96
|
|
18
|
Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells.
|
J Mol Med (Berl)
|
2012
|
0.93
|
|
19
|
The importance of endothelin axis in initiation, progression, and therapy of ovarian cancer.
|
Am J Physiol Regul Integr Comp Physiol
|
2010
|
0.92
|
|
20
|
Evidence for G-quadruplex in the promoter of vegfr-2 and its targeting to inhibit tumor angiogenesis.
|
Nucleic Acids Res
|
2013
|
0.90
|
|
21
|
LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis.
|
J Mol Med (Berl)
|
2012
|
0.90
|
|
22
|
Endothelin-1 cooperates with hypoxia to induce vascular-like structures through vascular endothelial growth factor-C, -D and -A in lymphatic endothelial cells.
|
Life Sci
|
2012
|
0.89
|
|
23
|
The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor.
|
Carcinogenesis
|
2014
|
0.88
|
|
24
|
Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression.
|
Exp Biol Med (Maywood)
|
2006
|
0.88
|
|
25
|
Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma.
|
Mol Cancer Ther
|
2006
|
0.88
|
|
26
|
β-arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury.
|
J Am Soc Nephrol
|
2013
|
0.88
|
|
27
|
Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo.
|
Am J Pathol
|
2003
|
0.88
|
|
28
|
Endothelin-1 promotes proteolytic activity of ovarian carcinoma.
|
Clin Sci (Lond)
|
2002
|
0.85
|
|
29
|
Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
|
Can J Physiol Pharmacol
|
2010
|
0.82
|
|
30
|
ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation.
|
Exp Biol Med (Maywood)
|
2006
|
0.81
|
|
31
|
Endothelin-B receptor blockade inhibits molecular effectors of melanoma cell progression.
|
J Cardiovasc Pharmacol
|
2004
|
0.81
|
|
32
|
Endothelin axis induces metalloproteinase activation and invasiveness in human lymphatic endothelial cells.
|
Can J Physiol Pharmacol
|
2010
|
0.81
|
|
33
|
Endothelin-1 acts as a survival factor in ovarian carcinoma cells.
|
Clin Sci (Lond)
|
2002
|
0.80
|
|
34
|
The endothelin A receptor and epidermal growth factor receptor signaling converge on β-catenin to promote ovarian cancer metastasis.
|
Life Sci
|
2012
|
0.79
|
|
35
|
Antitumor effect of green tea polyphenol epigallocatechin-3-gallate in ovarian carcinoma cells: evidence for the endothelin-1 as a potential target.
|
Exp Biol Med (Maywood)
|
2006
|
0.79
|
|
36
|
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody.
|
Mol Cancer Ther
|
2014
|
0.78
|
|
37
|
Convergent pathways link the endothelin A receptor to the beta-catenin: the beta-arrestin connection.
|
Cell Cycle
|
2009
|
0.78
|
|
38
|
Endothelin-1 stimulates cyclooxygenase-2 expression in ovarian cancer cells through multiple signaling pathways: evidence for involvement of transactivation of the epidermal growth factor receptor.
|
J Cardiovasc Pharmacol
|
2004
|
0.77
|
|
39
|
Beta-arrestin-1 mediates the endothelin-1-induced activation of Akt and integrin-linked kinase.
|
Can J Physiol Pharmacol
|
2010
|
0.77
|
|
40
|
Targeting endothelin receptor type A in human cervical carcinoma cells.
|
J Cardiovasc Pharmacol
|
2004
|
0.77
|
|
41
|
Therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma: efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan.
|
J Cardiovasc Pharmacol
|
2004
|
0.76
|
|
42
|
Endothelin receptor blockade inhibits the growth of human papillomavirus-associated cervical carcinoma.
|
Clin Sci (Lond)
|
2002
|
0.75
|
|
43
|
ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth in vitro.
|
Clin Sci (Lond)
|
2002
|
0.75
|